ERBB2 and colorectal carcinoma: Our study demonstrated that ctDNA can detect ERBB2 amplification in ~70% of the patients with ERBB2-amplified advanced CRC, suggesting that while ERBB2 amplification is detectable in most patients in the ctDNA, tissue testing is necessary to capture all ERBB2-amplified patients.